Breast cancer, version 3.2013

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 7, 2013, Pages 753-761

  Theriault, Richard L ^a   Carlson, Robert W ^b   Allred, Craig ^c   Anderson, Benjamin O ^d   Burstein, Harold J ^e   Edge, Stephen B ^f   Farrar, William B ^g   Forero, Andres ^h   Giordano, Sharon Hermes ^a   Goldstein, Lori J ⁱ   Gradishar, William J ^j   Hayes, Daniel F ^k   Hudis, Clifford A ^l   Isakoff, Steven J ^m   Ljung, Britt Marie E ⁿ   Mankoff, David A ^d   Marcom, P Kelly ^o   Mayer, Ingrid A ^p   McCormick, Beryl ^l   Pierce, Lori J ^k   Reed, Elizabeth C ^q   Schwartzberg, Lee S ^r   Smith, Mary Lou ^s   Soliman, Hatem ^t   Somlo, George ^u   Ward, John H ^v   Wolff, Antonio C ^w   Zellars, Richard ^w   Shead, Dorothy A ^x   Kumar, Rashmi ^x   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

^d SEATTLE CANCER CARE ALLIANCE   (United States)

^e DANA FARBER BRIGHAM AND WOMEN S CANCER CENTER   (United States)

^f ROSWELL PARK CANCER INSTITUTE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

ⁱ FOX CHASE CANCER CENTER   (United States)

^j NORTHWESTERN UNIVERSITY   (United States)

^k UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^l MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^m MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

ⁿ UNIVERSITY OF CALIFORNIA   (United States)

^o DUKE CANCER INSTITUTE   (United States)

^p VANDERBILT INGRAM CANCER CENTER   (United States)

^q NEBRASKA MEDICAL CENTER   (United States)

^r UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^s Research Advocacy Network   (United States)

^t H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^u CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^v UNIVERSITY OF UTAH   (United States)

^w JOHNS HOPKINS UNIVERSITY   (United States)

^x National Comprehensive Cancer Network   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

ALGORITHM; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL PRACTICE; HUMAN; METASTASIS; ONCOLOGY; PRACTICE GUIDELINE; PROTEIN DETERMINATION;

EID: 84880964487     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0098     Document Type: Article

References (19)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Wolff AC, Hammond MEH, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-145.
3. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010;28:92-98.
4. Carlson RW, Moench SJ, Hammond ME, et al. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):1-22.
5. Paik S, Bryant J, Tan-Chiu E, et al. Real-world performance of HER2 testing - National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852-854.
6. Perez EA, Suman VJ, Davidson NE, et al. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:3032-3038.
7. Roche PC, Suman VJ, Jenkins RB, et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002;94:855-857.
8. Scheuer W, Friess T, Burtscher H, et al. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res 2009;69:9330-9336.
9. Baselga J, Cortes J, Im SA, et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC). Cancer Res 2012;72(24 Suppl):S5-1.
10. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-119.
11. Swain S, Kim S-B, Cortes J, et al. Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2- positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 2012;72(24 Suppl):P5-18-26.
12. Cortés J, Baselga J, Im Y, et al. Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract 598.
13. Swain SM, Ewer MS, Cortes J, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2- positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist 2013;18:257-264.
14. Datko F, D'Andrea G, Dickler M, et al. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer. Cancer Res 2012;72(24 Suppl):P5-18-20.
15. Perez E, Lopez-Vega J, Mastro L, et al. A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: an open-label, two-cohort, phase II study (VELVET) [abstract]. J Clin Oncol 2012;30(Suppl 15):Abstract TPS653.
16. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010;28:1138-1144.
17. Cortes J, Fumoleau P, Bianchi GV, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:1594-1600.
18. Widdison WC, Wilhelm SD, Cavanagh EE, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006;49:4392-4408.
19. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783-1791.